Clinical trials: Throat Carcinoma
Head and Neck Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004094
- Testing
- carboplatin, fluorouracil, hydroxyurea
- Where
- 4 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma
Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma
This clinical study is designed as an open, single group, multi-center, phase 4 clinical study to assess the safety of Nimotuzumab in the treatment of nasopharyngeal carcinoma and to provide a more reasonable basis for clinical…
- Trial name
- NCT02293356
- Testing
- Nimotuzumab Injection
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
A Phase III Study of Radiotherapy With or Without Adjuvant C/T in Advanced Stage Nasopharyngeal Carcinoma Patients
To investigate the efficacy of adjuvant PFL chemotherapy after radiotherapy vs radiotherapy alone in AJC stage IV nasopharyngeal carcinoma patients.
- Trial name
- NCT00201344
- Testing
- Cisplatin,5-FU,Leucovorin
- Where
- Taiwan
- Volunteers
- 320 people
- Sponsor
- National Health Research Institutes, Taiwan
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
There is a significant unmet medical need for effective therapies for pediatric relapsed/refractory solid tumors. EGFR is highly and stably expressed in multiple pediatric solid tumor subtypes, and adult Phase I data of Becotatug…
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma, Lymphoepithelial Carcinoma, Rhabdomyosarcoma
- Trial name
- MRG003 (NCT07584499)
- Testing
- Becotatug Vedotin
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin
An International Study on Pediatric Patients With Rare Tumors.
The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.
- Conditions
- Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin, Gastrointestinal Stromal Tumor (GIST), Adrenocortical Tumor
- Trial name
- PARTNER (NCT07072143)
- Where
- Italy
- Volunteers
- 6,250 people
- Sponsor
- Azienda Ospedaliera di Padova
Nasopharyngeal Carcinoma (NPC)
Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma
The goal of this study is to investigate the outcomes of patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) or recurrent-metastatic nasopharyngeal carcinoma (RM-NPC) treated with a combination of immune…
- Trial name
- NCT06676293
- Testing
- Anti-PD1, asparaginase
- Where
- Taiwan
- Volunteers
- 8 people
- Sponsor
- Chang Gung Memorial Hospital
Nasopharyngeal Cancer
A Study of Nasopharyngeal Carcinoma From Guangdong
This prospective cohort study aims to establish prognostic models, to discover toxicity associated predictors and to validate randomized trials in clinical practice.
- Trial name
- NCT03003182
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NCP Susceptibility Gene(s)
The objective of this study is to characterize genes associated either with susceptibility or resistance to the development nasopharyngeal carcinoma (NPC) in a Chinese population where the incidence of NPC is as high as 50 in…
- Trial name
- NCT00341146
- Where
- China
- Volunteers
- 6,490 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma
LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)
Patients have a type of cancer called nasopharyngeal carcinoma (NPC) which has either come back, not gone away or is at high risk for coming back after the best treatment we know for this disease.
- Trial name
- NATELLA (NCT00516087)
- Testing
- Genetically modified CTLs
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Baylor College of Medicine
Nasopharyngeal Neoplasms, Carcinoma, Squamous Cell
Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)
To test the therapeutic ratio of additional chemotheray on advanced nasopharyngeal carcinoma.
- Trial name
- NCT00563927
- Testing
- Conventional RT, Cisplatin, 5-fluorouracil
- Where
- 4 sites in China
- Volunteers
- 340 people
- Sponsor
- Hospital Authority, Hong Kong
Nasopharyngeal Carcinoma
Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
This clinical study aims to evaluate the diagnostic performance of a new Epstein-Barr virus (EBV) C promoter methylation detection kit.
- Trial name
- NCT06445088
- Testing
- VCA-IgA, EBNA1-IgA, and EBV-DNA, EBV C Promoter Methylation Detection in nasopharyngeal swab samples
- Where
- 5 sites in China
- Volunteers
- 908 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC), Lymph Node Metastasis
A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)
(I) AI Model for Diagnosing Lymph Node Metastasis We developed an AI model to help diagnose whether a single lymph node in nasopharyngeal cancer has spread. The model uses MRI images of the lymph node and the area around it.
- Trial name
- NPC (NCT06829147)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Serial Plasma EBV DNA for Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southern China, Hong Kong, Taiwan, Singapore and Malaysia. It is highly associated with Epstein-Barr virus (EBV).
- Trial name
- NCT02476669
- Where
- Hong Kong
- Volunteers
- 900 people
- Sponsor
- The University of Hong Kong
Nasopharyngeal Carcinoma, Oral Mucositis
Prospective Observational Study to Predict Severe Oral Mucositis Associated With Chemoradiotherapy in Nasopharyngeal Carcinoma Based on Deep Learning
The goal of this observational study is to apply the CNN-based DL method to extract the three-dimensional spatial information of IMRT dose distribution to predict the occurrence probability of serious radiotherapy and…
- Trial name
- NCT06032767
- Testing
- observational group
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes
Patients have a type of cancer called nasopharyngeal carcinoma (NPC) that has either come back or not gone away after the best known standard treatments.
- Trial name
- CADEN (NCT00953420)
- Testing
- Docetaxel, Carboplatin, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Baylor College of Medicine
Nasopharyngeal Carcinoma (NPC)
Biomarker Analysis Data From a Randomized Phase II Study in Patients With Nasopharyngeal Carcinoma Treated With Chemotherapy and Radiotherapy
Clinicopathological and genomic data (Next generation sequencing and IHC/CISH) in available tissues were performed in patients with nasopharyngeal carcinoma who participated in a previously conducted randomized phase II study…
- Trial name
- NCT07741110
- Testing
- Next generation sequencing, Immunohistochemistry/CISH
- Volunteers
- 141 people
- Sponsor
- Hellenic Cooperative Oncology Group
Hodgkin Disease, Non-Hodgkin Lymphoma
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
The subject has a type of cancer or lymph gland disease associated with a virus called Epstein Barr Virus (EBV), which has come back, is at risk of coming back, or has not gone away after standard treatments.
- Conditions
- Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus, T/NK-lymphoproliferative Disease
- Trial name
- MABEL (NCT02287311)
- Testing
- MABEL CTLs, Cyclophosphamide, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Baylor College of Medicine
Otitis Media With Effusion After Nasopharyngeal Carcinoma
A Prospective, Randomized, Controlled Clinical Study of BET Combined With Tympanostomy Tube Insertion in the Treatment of Intractable OME After Radiotherapy for NPC
The primary purpose of this study is to compare balloon Eustachian tuboplasty (BET) combined with tympanostomy tube insertion and simply tympanostomy tube insertion in the treatment of otitis media with effusion (OME) in…
- Trial name
- NCT05449184
- Testing
- Balloon Eustachian Tuboplasty with Tympanostomy Tube Insertion, Tympanostomy Tube Insertion
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nasopharyngeal Carcinoma
Weekly Plasma EBV DNA for Non-metastatic Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southern China, Hong Kong, Taiwan, Singapore and Malaysia. It is highly associated with Epstein-Barr virus (EBV).
- Trial name
- NCT03830996
- Where
- Hong Kong
- Volunteers
- 100 people
- Sponsor
- The University of Hong Kong
NASOPHARYNGEAL CARCINOMA
Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL)
In this study NPC patient will receive 4 days of treatment with CD45 antibody followed by one dose of LMP1- and LMP2-CTL. From this, we can learn if treating the patient first with the CD45 antibody will also let LMP1- and…
- Trial name
- DELLA (NCT00515957)
- Testing
- genetically modified CTLs in combo with CD45 antibodies
- Sponsor
- Baylor College of Medicine